Crossmark

Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency

Crossref DOI link: https://doi.org/10.1007/s12328-025-02122-1

Published Online: 2025-04-10

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fukuda, Koshiro https://orcid.org/0000-0003-0464-8923
Kasuga, Akiyoshi https://orcid.org/0000-0002-2234-1135
Shigematsu, Yasuyuki https://orcid.org/0000-0001-5142-2906
Kato, Kenichiro https://orcid.org/0009-0007-8627-5038
Ito, Hiromichi https://orcid.org/0000-0003-0941-2055
Ueki, Arisa https://orcid.org/0000-0001-9205-5452
Okamoto, Takeshi https://orcid.org/0000-0001-9719-0282
Ozaka, Masato https://orcid.org/0000-0002-5666-1970
Takahashi, Yu https://orcid.org/0000-0003-3066-023X
Sasahira, Naoki https://orcid.org/0000-0002-0672-7214
License Information

Text and Data Mining valid from 2025-04-10

Version of Record valid from 2025-04-10
More Information

Article History

Received: 23 November 2024

Accepted: 21 March 2025

First Online: 10 April 2025

Declarations

:

: The authors declare no conflicts of interest.

: The patient provided informed consent for the publication of this report.

Document is current

Any future updates will be listed below